PET评价骨转移瘤

王俊起; 高硕

PET评价骨转移瘤

王俊起 , 高硕

文章导航 > 国际放射医学核医学杂志 > 2006, 30 > 2: (87-90)

引用本文:

Citation:

PET评价骨转移瘤

王俊起,
高硕

300052 天津, 天津医科大学总医院PET-CT中心
中图分类号: R817.4

PET in the evaluation of bone metastases

PET-CT Center, General Hospital of Tianjin Medical University, Tianjin 300052, China
CLC number: R817.4

摘要: 肿瘤骨转移会产生顽固性骨痛和脊髓受压等严重并发症,并对分期、治疗和判断预后产生深远的影响,因而探测骨转移是制定治疗计划的重要部分。骨转移瘤发现频率因原发肿瘤的类型和所用检查手段不同而不同,虽然目前核素骨扫描是探测骨转移瘤最常用的手段,但其对骨转移瘤的诊断效能仍有一定限度。与^99mTc-亚甲基二膦酸盐(^99mTc-MDP)骨显像相比,¹⁸F-氟化钠(¹⁸F-NaF)和¹⁸F-氟代脱氧葡萄糖(¹⁸F-FDG) PET是分别从骨转移瘤产生的成骨反应和骨转移瘤本身的代谢活性角度进行评价的两种正电子示踪剂,结合PET的高度空间分辨率,特别是最近迅速应用于临床的PET-CT技术,使得正电子体层显像在全身骨骼恶性疾病评价上的准确性进一步提高。
- 骨肿瘤 /
- 肿瘤转移 /
- 体层摄影术,发射型计算机 /
- ¹⁸F-氟化钠 /
- ¹⁸F-氟脱氧葡萄糖 /
- ^99mTc-亚甲基二膦酸盐
Abstract: The skeleton is one of the most common metastatic sites in patients with maligancy skeletal metastases are clinically significant because of associated symptoms, complications such as pathological fracture and their profound significance for staging, treatment and prognosis. Detection of bone metastases is, thus, an important part of treatment planning. The frequency with which metastases are detected varies considerably with the type of primary tumor and with the methodology utilized for detection. Bone scan is the most common modality in detection bone metastases. But its accuracy in early stage of bone metastases is limited. ¹⁸F-NaF and ¹⁸F-FDG are two different positron tracers, which can detect bone metastases by osteoblastic reaction of bone to the presence of tumors and directly tumor imaging, separately. Combination with the high resolution of PET, especialy the PE-CT which also provide a better anatomic localization, the accuracy of detection of bone metastases was improved significantly.
- Bone neoplasms /
- Neoplasm metastases /
- Tomography,emission-computed /
- ¹⁸F-sodi-um fluoride /
- ¹⁸F-fluorodeoxyglucose /
- ^99mTc-methylene diphosphoate
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Rubens RD.Bone metastases-incidence and complications.In Rubens RD,Mundy GR.Cancer and the skeleton.London:Martin Dunitz,2000.33-42.
[2]	Schirrmeister H,Buck A,Guhlmann A,et al.Anatomical distribution and sclerotic activity of bone metastases from thyroid cancer assessed with F-18 sodiumfluoride PET..Thyroid,2001,11(7):677-683.
[3]	Schirrmeister H,Guhlmann A,Elsner K,et al.Sensitivity in detecting osseous lesions depends on anatomic localization:planar bone scintigraphy versus ¹⁸F PET.J Nucl Med,1999,40(10):1623-1629.
[4]	Hetzel M,Arslandemir C,Konig HH,et al.F-18 NaF PET for detection of bone metastases in lung cancer:accuracy,costeffectiveness and impact on patient management.J Bone Miner Res,2003,18(12):2206-2214.
[5]	Schirrmeister H,Glatting G,Hetzel J,et al.Prospective evaluation of the clinical value ofplanar bone scans,SPECT and (18)F-labeled NaF PET in newly diagnosed lung cancer.J Nucl Med,2001,42(12):1800-1804.
[6]	Schirrmeisier H,Buck AK,Bergmann L,et al.PET for staging of solitary plasmacytoma.Cancer Biother Radiopharm,2003,18(5):841-845.
[7]	Wu HC,Yen RF,Shen YY,et al.Comparing whole body ¹⁸F-2-deoxyglucose PET and ^99mTc MDP bone scan to detect bone metastases in patients with renal cell carcinomas-a preliminary report.J Cancer Res Clin Oncol,2002,128(9):503-506.
[8]	Marom EM,McAdams HP,Erasmus JJ,et al.Staging non-small cell lung cancer with whole-body PET.Radiology,1999,212(3):803-809.
[9]	Cook GJ,Houston S,Rubens R,et al.Detection of bone metastases in breast cancer by ¹⁸F-FDG PET:differing metabolic activity in osteoblastic and osteolytic lesions.J Clin Oncol,1998,16(10):3375-3379.
[10]	Franzius C,Sciuk J,Daldrup-Link HE,et al.FDG PET for detection of osseous metastases from malignant primary bone tumours:comparison with bone scintigraphy.Eur J Nucl Med,2000,27(9):1305-1311.
[11]	Gallowitsch H J,Kresnik E,Gasser J,et al.F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma:A comparison to conventional imaging.Invest Radiol,2003,38(5):250-256.
[12]	Jadvar H,Pinski JK,Conti PS.FDG PET in suspected recurrent and metastatic prostate cancer.Oncol Rep,2003,10(5):1485-1488.
[13]	Gayed I,Vu T,Johnson M,et al.Comparison of bone and 2-dooxy-2-[¹⁸F]fluoro-D-glucose PET in the evaluation of bony metastases inlung cancer.Mol Imaging Biol,2003,5(1):26-31.
[14]	Bury T,Barreto A,Daenen F,et al.Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer.Eur J Nucl Med,1998,25(9):1244-1247.
[15]	Stafford SE,Gralow JR,Schubert EK,et al.Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy.Acad Radiol,2002,9(8):913-921
[16]	Fogelman I,Cook G,Israel O,et al.Positron emission tomography and bone metastaese.Semin Nucl Med,2005,35(2):135-142.
[17]	Israel O,Mor M,Guralnik L,et al.Is ¹⁸F-FDG PET/CT useful for imaging and management of patients with suspected occult recurrence of cancer?.J Nucl Med,2004,45(12):2045-2051.
[18]	Even-Sapir E,Metser U,Flusser G,et al.Assessment of malignant skeletal disease:initial experience with ¹⁸F-fluoride PET/CT and comparison between ¹¹C-fluoride PET and ¹⁸F-fluoride PET/CT.J Nucl Med,2004,45(2):272-278.
[19]	Ho-Shon I,Fogelman I.F-18 FDG PET and benign fractures.Clin Nucl Med,2003,28(3):171-175.

[1]	叶慧 , 莫逸 , 谢爱民 , 彭翔 . ¹⁸F-氟脱氧葡萄糖PET-CT与99nTc-亚甲基二膦酸盐骨显像诊断转移性骨肿瘤的对比研究. 国际放射医学核医学杂志, 2008, 32(3): 147-150.
[2]	陈跃 . 颅内肿瘤放射治疗后¹⁸F-氟代脱氧葡萄糖PET的临床意义. 国际放射医学核医学杂志, 2006, 30(2): 97-99.
[3]	王俊起 , 高硕 , 李彦生 . ¹⁸F-氟化钠PET和PET-CT诊断肺癌骨转移的对比研究. 国际放射医学核医学杂志, 2009, 33(2): 68-72. doi: 10.3760/cma.j.issn.1673-4114.2009.02.002
[4]	张胤 , 陈跃 . ¹⁸F-氟化钠PET/CT诊断肿瘤骨转移应用进展. 国际放射医学核医学杂志, 2015, 39(1): 96-102. doi: 10.3760/cma.j.issn.1673-4114.2015.01.020
[5]	张悦 . ¹⁸F-氟脱氧葡萄糖PET和PET-CT在结直肠癌术后复发或转移中的应用价值. 国际放射医学核医学杂志, 2007, 31(1): 34-36.
[6]	刘超 , 邓智勇 , 刘鹏杰 , 贾莉 . ⁸⁹SrCL₂与唑来膦酸联合治疗乳腺癌转移性骨肿瘤的疗效分析. 国际放射医学核医学杂志, 2014, 38(5): 300-303. doi: 10.3760/cma.j.issn.1673-4114.2014.05.006
[7]	黄建敏 , 曲雁 , 潘莉萍 . 恶性骨肿瘤多药耐药的⁹⁹Tc^m-MIBI体层显像研究. 国际放射医学核医学杂志, 2005, 29(4): 169-170.
[8]	黄喆敏 , 左传涛 , 管一晖 . ¹⁸F-氟脱氧葡萄糖的脑肿瘤PET. 国际放射医学核医学杂志, 2007, 31(3): 163-165,172.
[9]	彭添兴 , 吴华 . ¹⁸F-氟脱氧葡萄糖以外新型PET肿瘤显像剂. 国际放射医学核医学杂志, 2007, 31(1): 9-12.
[10]	邢岩 , 赵晋华 . ¹⁸F-氟脱氧葡萄糖PET及PET-CT早期诊断肿瘤复发. 国际放射医学核医学杂志, 2007, 31(6): 341-344.

点击查看大图

计量

文章访问数: 1185
HTML全文浏览量: 91
PDF下载量: 3

PET评价骨转移瘤

王俊起
高硕

300052 天津, 天津医科大学总医院PET-CT中心

收稿日期: 2006-08-21

关键词:

摘要: 肿瘤骨转移会产生顽固性骨痛和脊髓受压等严重并发症,并对分期、治疗和判断预后产生深远的影响,因而探测骨转移是制定治疗计划的重要部分。骨转移瘤发现频率因原发肿瘤的类型和所用检查手段不同而不同,虽然目前核素骨扫描是探测骨转移瘤最常用的手段,但其对骨转移瘤的诊断效能仍有一定限度。与^99mTc-亚甲基二膦酸盐(^99mTc-MDP)骨显像相比,¹⁸F-氟化钠(¹⁸F-NaF)和¹⁸F-氟代脱氧葡萄糖(¹⁸F-FDG) PET是分别从骨转移瘤产生的成骨反应和骨转移瘤本身的代谢活性角度进行评价的两种正电子示踪剂,结合PET的高度空间分辨率,特别是最近迅速应用于临床的PET-CT技术,使得正电子体层显像在全身骨骼恶性疾病评价上的准确性进一步提高。